welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Thetis Pharmaceuticals Awarded Key Patent on HEALER Technology
Thetis Pharmaceuticals LLC, a privately-held biopharmaceutical company focused on gastrointestinal and cardiometabolic diseases, announced today that the USPTO has granted patent US 9,242,008 providing composition of matter protection for two Thetis development candidates, TP-252 for familial adenomatous polyposis and TP-452 for dyslipidemia. The allowed claims include pharmaceutical compositions that are mineral amino-acid based derivatives of fatty acids. National filings outside of the United States are underway.
expertly curated content related to this topic
-
Chemoprevention of hereditary colon cancers: time for new strategiesColorectal cancer (CRC) is potentially p...
-
Familial adenomatous polyposis monitoring, Whipple procedure gave my husband more timeWhen he was 15, my husband Jesse underwe...
-
Mayo Clinic Researcher Finds Potential Target to Control Rare Genetic Disease That Strikes in Teen YearsA new study from researchers at Mayo Cli...
-
Label-Free Global Serum Proteomic Profiling Reveals Novel Celecoxib-Modulated Proteins in Familial Adenomatous Polyp...Celecoxib, a selective inhibitor of cycl...
-
Neha Patel, MDAssistant Professor, Internal Medicine a...
-
Matthew Kalady, MDMatthew Kalady, MD, holds the Krause-Lie...
-
A Total Laparoscopic Approach Reduces the Infertility Rate after Ileal Pouch-Anal Anastomosis: A 2-Center StudyOBJECTIVE: To assess the infertility ra...